top of page

Pelabresib Phase 3 Trial Shows Significant Spleen Volume Reduction in Myelofibrosis

MorphoSys announced positive topline results from the Phase 3 MANIFEST-2 study evaluating pelabresib in combination with ruxolitinib compared to placebo plus ruxolitinib in JAK inhibitor-naïve adult patients with myelofibrosis.


MorphoSys announced positive topline results from the Phase 3 MANIFEST-2 study evaluating pelabresib in combination with ruxolitinib compared to placebo plus ruxolitinib in JAK inhibitor-naïve adult patients with myelofibrosis.

The trial met its primary endpoint, as the combination therapy demonstrated a statistically significant and clinically meaningful improvement in the proportion of patients achieving at least a 35% reduction of spleen volume at week 24.

Want to read more?

Subscribe to www.gmpnsf.org to keep reading this exclusive post.

Subscribe Now
29 views0 comments
bottom of page